IQVIA Holdings Inc.
NYSE:IQVMedical - Diagnostics & Research
-$3.13 today
- Market cap
- $42.49B
- Beta
- 1.22
- P/E (TTM)
- 20.4
- EPS (TTM)
- $8.22
Volume 1.40M
Average 1.62M
IQV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
IQVIA Holdings Inc.NYSE: IQV
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of $790M rose 1.2% year over year, behind the +5.3% change in trailing-twelve-month EBITDA. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at +0.3% a year.
Context
- EBITDA amounted to 18.0% of revenue in FY2025, down 4.4 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 14 analysts of $3.99B (+36.0%) for the fiscal year ending Dec 2026, a step up from the -14.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $790M-2.2% QoQ
- Last fiscal yearDec 2025
- $2.94B-14.9% YoY
- LTMJun 2026
- $3.53B+5.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.2% | +31.8% | +30.6 pp |
| 1 year | -14.9% | +36.0% | +50.9 pp |
| 3-year CAGR | +0.3% | +15.5% | +15.1 pp |
| 5-year CAGR | +13.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 2.94B USD
- Year-over-year change
- -14.9%
- 4-year CAGR
- +1.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.94B | -14.9% |
| FY2024 | 2024-12-31 | 3.45B | +6.1% |
| FY2023 | 2023-12-31 | 3.26B | +11.9% |
| FY2022 | 2022-12-31 | 2.91B | +5.1% |
| FY2021 | 2021-12-31 | 2.77B | — |
EBITDA vs competitors
How IQV compares with its peers on the latest reported figures
- IQV's LTM Jun 2026 EBITDA of $3.53B is the highest of the 9 companies compared; the peer median is $160.87M.
- Its year-over-year change of +5.3% is the 5th highest of 9, against a peer median of +4.1%.
- EBITDA amounts to 20.8% of revenue for IQV, versus a peer median of 18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.53B | +5.3% | +0.3% | 20.8% | |
| LTM Jul 2026 | $1.37B | +25.9% | +32.3% | 39.7% | |
| LTM Jun 2026 | $1.25B | -9.3% | -15.5% | 15.1% | |
| LTM Sep 2026 | $643.55M | +17.5% | +22.8% | 22.7% | |
| LTM Jun 2026 | $220.47M | -58.3% | -25.3% | 5.5% | |
| LTM Mar 2026 | $101.27M | +78.1% | -1.9% | 24.1% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $81.2M | +109.5% | — | 3.0% |
| LTM Sep 2026 | -$108.97M | -19.4% | — | 7.2% | |
| LTM Mar 2026 | -$192.37M | -1267.9% | — | 63.6% | |
| Peer median (excluding IQV) | $160.87M | +4.1% | -1.9% | 18.9% | |
Competitors are the stored peer set for IQV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.87B | 14.41B | 14.98B | 15.41B | 16.31B |
| Cost of Revenue | 9.23B | 9.38B | 9.75B | 10.03B | 10.88B |
| Gross Profit | 4.64B | 5.03B | 5.24B | 5.38B | 5.43B |
| Gross Margin | 33.5% | 34.9% | 35.0% | 34.9% | 33.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.96B | 2.07B | 2.05B | 1.99B | 1.99B |
| Operating Expenses | 3.25B | 3.23B | 3.26B | 3.17B | 3.25B |
| Depreciation & Amortization | 1.26B | 1.13B | 1.13B | 1.11B | 640M |
| EBITDA | 2.77B | 2.91B | 3.26B | 3.45B | 2.94B |
| EBITDA Margin | 19.9% | 20.2% | 21.7% | 22.4% | 18.0% |
| Operating Income | 1.39B | 1.8B | 1.98B | 2.2B | 2.18B |
| Operating Margin | 10.0% | 12.5% | 13.2% | 14.3% | 13.4% |
| Interest Income | 6M | 13M | 36M | 47M | 45M |
| Interest Expense | 375M | 416M | 672M | 670M | 729M |
| Other Income / Expenses | (259M) | (448M) | (518M) | (533M) | (569M) |
| Income Before Tax | 1.13B | 1.35B | 1.46B | 1.67B | 1.61B |
| Pre-Tax Margin | 8.2% | 9.4% | 9.7% | 10.8% | 9.9% |
| Income Tax Expense | 163M | 260M | 101M | 296M | 252M |
| Net Income | 966M | 1.09B | 1.36B | 1.37B | 1.36B |
| Net Margin | 7.0% | 7.6% | 9.1% | 8.9% | 8.3% |
| EPS (Basic) | 5.05 | 5.82 | 7.39 | 7.57 | 7.91 |
| EPS (Diluted) | 4.95 | 5.72 | 7.29 | 7.49 | 7.84 |
| Weighted Avg Shares | 191.4M | 187.6M | 183.8M | 181.3M | 171.9M |
| Weighted Avg Shares (Diluted) | 195M | 190.6M | 186.3M | 183.4M | 173.5M |
IQVIA Holdings Inc.
NYSE:IQV
Intrinsic Alpha fair value
Locked
Current Price
$257.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.